{
  "trial_id": "NCT03529955",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "Must understand the risks and the benefits/purpose of the study and provide signed and dated informed consent.",
      "label": "unknown"
    },
    {
      "criterion": "Must be 18 years at time of signing the informed consent form.",
      "label": "met"
    },
    {
      "criterion": "Willing to participate in all required evaluations and procedures in the study including the ability to swallow pills without difficulty.",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Increasing or changing dose of topical therapy within 14 days of study day 0 (including but not limited to topical corticosteroids, tacrolimus, pimecrolimus).",
      "label": "triggers"
    },
    {
      "criterion": "History of any clinically significant (as determined by the investigators) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major uncontrolled disease.",
      "label": "unknown"
    }
  ],
  "notes": "Patient has a history of C diff infections and recent antibx use. She was treated with Vanco for an extended course of 6 weeks given her recurrent C diff.",
  "_meta": {
    "topic_id": "6",
    "trial_id": "NCT03529955",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}